Grants

Below is an overview of the grants supporting the lab’s research efforts. Each entry includes the project’s duration, goals, and funding source. These initiatives reflect the lab’s commitment to innovation and collaboration across multiple disciplines, enabled by invaluable support from funding agencies.

Current

R01NS128486-01

Duration: 07/2022 – 06/2027 (NIH/NINDS)
View More

Role: Contact PI
Large-scale harmonization and integration of multi-modal ADNI data for the early detection of Alzheimer’s disease and related dementias. This study aims to aggregate data across multiple cohorts, enabling better clinical tools for future disease-modifying therapies.

Wyeth Krueger Award (Varghese)

Duration: 09/2021 – 08/2026 (Y)
View More

Role: PI
Validating a Hybrid AI-Based Framework for Breast Masses Using Contrast-Enhanced Ultrasound (CEUS). This work aims to reduce unnecessary biopsies, especially among underserved breast cancer patients.

Pending

NIH/NCI R01 (Phantom-based CT Radiomics)

Duration: 1 calendar month
View More

Role: PI
Evaluate the feasibility of using robust, reproducible, and repeatable (RRR) metrics from a novel CT-based radiomics phantom as a feature-reduction technique. Investigate strategies to standardize radiomic features across multiple institutions.

Past

Wright Foundation

Duration: 07/01/19 – 06/30/21
View More

Role: PI
Characterizing Breast Masses Using an Integrative Framework of Machine Learning and Radiomics. Proposed a CEUS-based radiomics + machine learning solution for breast lesions.

BD2K 2017

Duration: 01/01/17 – 05/31/17 (Big Data to Knowledge)
View More

Role: PI
Big Data to Clinical Knowledge: Using Radiomics and Machine Learning to Go Beyond the Visual Assessment of Medical Images. Applied advanced machine learning to select features for tasks ranging from tumor malignancy stratification to prostate tumor grading.

ACS (IRG-16-181-57)

Duration: 09/01/19 – 08/31/20
View More

Role: PI
Radiomic Signature of CD+ T Cell Infiltration and PD-L1 Expression in Metastatic Renal Cell Carcinoma. Explored relationships between immune-histochemical features and radiomic data in ccRCC.

Dean’s Pilot Grant

Duration: 03/01/20 – 08/31/21
View More

Role: PI
Reliability Assessment of CT-based Radiomics Metrics in Tissue Characterization. Designed an imaging-based phantom study to standardize CT-radiomics metrics.

Samsung

Duration: 08/15/18 – 08/15/21
View More

Role: Co-Investigator
Assessing the Role of Contrast-Enhanced Ultrasound and MV Flow™ Technology of Samsung RS85 in the Evaluation of Renal Masses. Differentiated benign from malignant renal masses using real-time CEUS.

RSNA (Fullenkamp)

Duration: 07/01/19 – 06/30/20 (Radiological Society of North America)
View More

Role: Co-Investigator
Predicting CD8+ T Cell Infiltration in Renal Cell Carcinoma Using Radiomic Signatures. Investigated how immune cell infiltration correlates with radiomic features in ccRCC.

RSNA (Liu)

Duration: 07/01/19 – 06/30/20
View More

Role: Co-Investigator
Radiogenomics Analysis of TCGA Muscle Invasive Bladder Carcinoma. Assessed relationships between CT texture features and genomic data.

RSNA (Fields)

Duration: 07/01/19 – 06/30/20
View More

Role: Co-Investigator
Radiomic Texture Analysis of Quantitative Magnetic Resonance Imaging of Soft-Tissue Sarcomas. Studied how MRI-based texture features reflect sarcoma behavior.

CTSI (Zahoor)

Duration: 06/01/19 – 05/31/20 (Clinical and Translational Science Institute)
View More

Role: Co-Investigator
Retrospective Analysis of Patients with RCC Treated at LAC+USC Medical Center and USC Norris. Explored immune-histochemical and radiomic correlations in ccRCC.

RMS (Yap)

Duration: 06/01/18 – 05/31/19 (Radiological Society of North America)
View More

Role: Co-Investigator
The Shapely Renal Mass: Quantitative Contour Evaluation of Renal Cell Carcinoma. Developed a radiomics model using contrast-enhanced CT to evaluate shape metrics in predicting RCC behavior.

ACG (Buxbaum)

Duration: 07/01/18 – 06/30/19 (American College of Gastroenterology)
View More

Role: Co-Investigator
Quantitative Metrics in Endoscopic Contrast-Enhanced Ultrasound of the Pancreas. Explored advanced quantitative CEUS metrics for pancreatic lesions.

RSNA (Lau)

Duration: 06/01/18 – 05/31/19
View More

Role: Co-Investigator
Association of CT Texture and Epigenomics in Clear Cell Renal Carcinoma. Explored how CT-based texture features relate to epigenetic signatures in ccRCC.

STR (Lin)

Duration: 07/01/18 – 06/30/19 (Society of Thoracic Radiology)
View More

Role: Co-Investigator
Evaluation of Lung Cancer Treatment Response to SBRT Utilizing Volumetric Dynamic Contrast-Enhanced CT and Texture Analysis. Studied how lung tumors respond to stereotactic body radiation therapy.

DPF2016 (Conti)

Duration: 12/01/16 – 11/31/17 (Dean’s Pilot Fund)
View More

Role: Co-Investigator
Utility of Preclinical PET/CT Imaging of αvβ6 Integrin for Molecular Stratification of Pulmonary Fibrosis. Developed multimodality molecular imaging probes targeting αvβ6 integrin.

CTSI2017 (Duddalwar)

Duration: 02/01/17 – 01/31/18
View More

Role: Co-Investigator
A Novel Radioepigenomics Approach to Discriminate Aggressive from Indolent Renal Cell Carcinoma. Combined radiomics + epigenomics to identify aggressive RCC phenotypes.

CTSI2017 (King)

Duration: 02/01/17 – 01/31/18
View More

Role: Co-Investigator
Time Intensity Curve Analysis in Contrast-Enhanced Ultrasound Evaluation of EphB4 as a Therapeutic Target in RCC. Evaluated EphB4 as a treatment target using quantitative CEUS of renal masses.

SAR2017 (King)

Duration: 02/01/17 – 01/31/18 (Society of Abdominal Radiology)
View More

Role: Co-Investigator
Time Intensity Curve Analysis in Contrast-Enhanced Ultrasound Evaluation of EphB4 as a Therapeutic Target in RCC. Similar to CTSI2017, focusing on quantitative CEUS for evaluating EphB4 in RCC.

RMS1621 (Fan)

Duration: 06/01/17 – 05/31/18 (RSNA)
View More

Role: Co-Investigator
Radiomics Evaluation of Bladder Cancer: Differentiating Transitional Cell Carcinoma from Micropapillary Carcinoma. Proposed a radiomics solution for earlier detection of MPCs, aiming to improve outcomes.

Whittier Foundation

Duration: 03/01/17 – 02/28/18
View More

Role: Co-Investigator
Utility of a Novel Radioepigenomics Approach to Discriminate Aggressive from Indolent Clear Cell Renal Cell Carcinoma. Developed a radiomics + epigenomics solution to differentiate malignant ccRCC from indolent disease.